Alkermes同意以最多21亿美元购买Avadel,以扩大其CNS药物组合。 Alkermes agrees to buy Avadel for up to $2.1 billion to expand its CNS drug portfolio.

Alkermes plc已同意收购Avadel制药公司,其交易价值高达21亿美元,旨在扩大其在中枢神经系统紊乱方面的投资组合。 Alkermes plc has agreed to acquire Avadel Pharmaceuticals plc in a deal valued up to $2.1 billion, aiming to expand its portfolio in central nervous system disorders. 2025年10月22日宣布的收购令Avadel的股票暴涨, The acquisition, announced on October 22, 2025, sent Avadel's stock soaring while Alkermes shares declined. 该交易经监管批准后,标志着阿尔克梅斯的一项战略举措,目的是加强其在特种药品中的地位。 The transaction, subject to regulatory approval, marks a strategic move for Alkermes to strengthen its position in specialty pharmaceuticals.